EWSR1 and neoplasm: Determining precisely how the ERBB and other kinase signaling pathways are dysregulated and co-opted by the EWS-WT1 chimeric transcription factor to drive tumor progression remains an open question and one that we can begin to investigate more effectively with these new DSRCT models.